Wedoany.com Report-Jun 3, Sanofi S.A., based in Paris, France, has agreed to acquire Blueprint Medicines Corp., a U.S. biopharmaceutical company specializing in systemic mastocytosis (SM) and other KIT-driven diseases. The acquisition, announced on May 30, 2025, includes Ayvakit/Ayvakyt (avapritinib), an approved treatment for advanced and indolent systemic mastocytosis in the U.S. and EU, along with Blueprint’s pipeline, featuring elenestinib and BLU-808, a selective KIT inhibitor for immunological disorders.

Ayvakit/Ayvakyt is the only approved therapy for systemic mastocytosis, a rare condition involving abnormal mast cell accumulation in organs like bone marrow, skin, and the gastrointestinal tract. The acquisition strengthens Sanofi’s immunology portfolio, leveraging Blueprint’s established network among allergists, dermatologists, and immunologists. Elenestinib, a next-generation SM treatment, is under evaluation in a phase 2/3 study, while BLU-808 targets a range of inflammatory diseases.

Sanofi will pay $129.00 per Blueprint share in cash, valuing the deal at approximately $9.1 billion. Shareholders will also receive one non-tradeable contingent value right (CVR), offering potential milestone payments of $2 and $4 per CVR for BLU-808’s clinical and regulatory milestones, respectively, bringing the total equity value to about $9.5 billion. The offer represents a 27% premium over Blueprint’s closing price on May 30, 2025, and a 34% premium over its 30-day volume-weighted average price.

Paul Hudson, CEO of Sanofi, said: “The proposed acquisition of Blueprint Medicines represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world’s leading immunology company. This acquisition is fully aligned with our strategic intent to strengthen our existing therapeutic areas, to bring relevant and differentiated medicines to patients and to secure attractive returns to our shareholders.”

Kate Haviland, CEO of Blueprint Medicines, said: “Since our founding, Blueprint Medicines has worked at the intersection of scientific innovation and operational excellence. I’m incredibly proud of the medical innovations our people have created and delivered to patients. We have translated our unique scientific understanding of mast cell biology into a portfolio of important therapies including Ayvakit – the first and only medicine approved to treat the root cause of systemic mastocytosis – and worked collaboratively with communities to improve standards of care and patient outcomes.”

Ayvakit generated $479 million in net revenue in 2024 and $150 million in the first quarter of 2025, reflecting over 60% growth year-on-year. The acquisition, funded by cash and new debt, is expected to close in the third quarter of 2025, subject to regulatory approvals and customary conditions. It will enhance Sanofi’s gross margin immediately and boost operating income and earnings per share from 2026.